Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02451943
Registration number
NCT02451943
Ethics application status
Date submitted
20/05/2015
Date registered
22/05/2015
Date last updated
17/04/2024
Titles & IDs
Public title
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma
Query!
Scientific title
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma
Query!
Secondary ID [1]
0
0
I5B-MC-JGDJ
Query!
Secondary ID [2]
0
0
15677
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ANNOUNCE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Soft Tissue Sarcoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Sarcoma (also see 'Bone') - soft tissue
Query!
Cancer
0
0
0
0
Query!
Bone
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Olaratumab
Treatment: Drugs - Doxorubicin
Treatment: Drugs - Placebo
Experimental: Doxorubicin + Olaratumab - 75 milligrams per meter squared (mg/m^2) doxorubicin administered intravenously (IV) on day 1 of each 21-day cycle for 8 cycles plus 20 milligrams per kilogram (mg/kg) dose of olaratumab administered IV on day 1 and day 8 of cycle 1 and 15 mg/kg olaratumab administered IV on day 1 and day 8 of cycles 2-8. Beginning with cycle 9, 15 mg/kg olaratumab administered IV on day 1 and day 8 of each subsequent 21-day cycle until documented progressive disease (PD) or discontinuation for any other reason.
Placebo Comparator: Doxorubicin + Placebo - 75 mg/m^2 doxorubicin administered IV on day 1 of each 21-day cycle for 8 cycles plus placebo (equivalent volume) administered IV on day 1 and day 8 for 8 cycles. Beginning with cycle 9, placebo (equivalent volume) administered on days 1 and 8 of each subsequent 21-day cycle until PD or discontinuation for any other reason.
Treatment: Drugs: Olaratumab
Administered IV
Treatment: Drugs: Doxorubicin
Administered IV
Treatment: Drugs: Placebo
Administered IV
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
Overall survival was defined as the time from the date of randomization to the date of death due to any cause. For each participant, prior to data analysis, a reasonable effort was made to obtain the most up-to-date status (date of death or last date known to be alive). For any participant not known to have died as of the data cutoff date, OS was censored at the date the participant was last known to be alive. For any participant who withdrew consent for survival follow-up, OS was censored at the last date for which the participant provided consent for follow-up contact. The Kaplan-Meier method was used to estimate median parameters.
Query!
Timepoint [1]
0
0
Randomization to Date of Death Due to Any Cause (Up to 35.8 Months)
Query!
Primary outcome [2]
0
0
Overall Survival (OS) Leiomyosarcoma (LMS)
Query!
Assessment method [2]
0
0
Overall survival was defined as the time from the date of randomization to the date of death due to any cause. For each participant, prior to data analysis, a reasonable effort was made to obtain the most up-to-date status (date of death or last date known to be alive). For any participant not known to have died as of the data cutoff date, OS was censored at the date the participant was last known to be alive. For any participant who withdrew consent for survival follow-up, OS was censored at the last date for which the participant provided consent for follow-up contact. The Kaplan-Meier method was used to estimate median parameters.
Query!
Timepoint [2]
0
0
Randomization to Date of Death Due to Any Cause (Up to 35.8 Months)
Query!
Secondary outcome [1]
0
0
Progression Free Survival (PFS)
Query!
Assessment method [1]
0
0
PFS was defined by (Response Evaluation Criteria In Solid Tumors RECIST v.1.1) as the time from the date of randomization to the first date of radiologic disease progression or death due to any cause. Progressive Disease (PD) is at least 20% increase in sum of diameters of target lesions, with reference being the smallest sum on study and plus absolute increase of at least 5 millimeter (mm), or unequivocal progression of non-target lesions, or 1 or more new lesions. Censoring for death or PD due to increase sum of target lesions is defined for each participant as the time from the date of randomization to the first date of radiographic documentation of 1 or more lesions. Censoring for death without progression is defined as the date of death if there is no prior or concurrent radiologic disease progression.
Query!
Timepoint [1]
0
0
Randomization to Objective Progression or Death Due to Any Cause (Up to 35.8 Months)
Query!
Secondary outcome [2]
0
0
Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Response Rate (ORR)
Query!
Assessment method [2]
0
0
ORR was defined as the percentage of participants achieving a best overall response of complete response (CR) + partial response (PR). CR is the disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (<10 mm short axis). PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Tumor marker results must have normalized. Best overall response is classified based on the overall responses assessed by study investigators according to RECIST v1.1.
Query!
Timepoint [2]
0
0
Randomization to Objective Disease Progression or Death Due to Any Cause (Up to 35.8 Months)
Query!
Secondary outcome [3]
0
0
Percentage of Participants With a Best Overall Response of CR, PR, or Stable Disease (SD): Disease Control Rate (DCR)
Query!
Assessment method [3]
0
0
DCR was defined as the percentage of randomized participants achieving a best overall response of CR, PR, or SD per RECIST v.1.1. CR is the disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (<10 mm short axis). PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Tumor marker results must have normalized. PD is at least 20% increase in sum of diameters of target lesions, with reference being the smallest sum on study and plus absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Query!
Timepoint [3]
0
0
Randomization to Objective Disease Progression or Death Due to Any Cause (Up to 45 Months)
Query!
Secondary outcome [4]
0
0
Time to First Worsening on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Scores
Query!
Assessment method [4]
0
0
Time to first worsening was calculated as the time from the first study drug dose to the first observation of worsening according to the EORTC QLQ-C30 Scoring Manual (Fayers et al. 2001). The EORTC QLQ-C30 self-reported general cancer instrument consists of 30 total items covered by 1 of 3 dimensions (1 global health status/QoL total score, 5 functional subscales [physical, role, cognitive, emotional, and social]), and 9 symptom subscales [fatigue/nausea/vomiting/pain/dyspnea/insomnia/appetite loss/constipation/diarrhea]). There are 28 questions answered on a 4-point scale where 1=Not at all (best) to 4=Very Much (worst) and 2 questions answered on a 7-point scale where 1=Very poor (worst) to 7= Excellent (best). A linear transformation was used to obtain total score ranging from 0 to 100 where "worsening" was defined as an increase of at least 10 points for the symptom scales or a decrease of at least 10 points for the functional scales and the global health status/QoL scale.
Query!
Timepoint [4]
0
0
Randomization (Cycle 1) through Follow-up (Up to 35.8 Months)
Query!
Secondary outcome [5]
0
0
Change From Baseline to Maximum Improvement in Health Status Index Score on the EuroQol 5-Dimension 5-Level (EQ-5D-5L)
Query!
Assessment method [5]
0
0
The EQ-5D-5L is a standardized measure of health status used to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of a descriptive system of the respondent's health which comprises the following 5 dimensions: (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Health status was calculated from a set of item weights to derive a score of 0 to 1, with 1 representing the best health status. United Kingdom (UK) weights were applied. The analysis includes all cycles for which at least 25% of participants in each arm have an assessment. For each participant a change from baseline was calculated for every post-baseline assessment by subtracting the baseline assessment result from the current assessment result. Maximum improvement (over baseline) was determined from the set of all post-baseline change scores.
Query!
Timepoint [5]
0
0
Randomization through Follow-up (Up to 35.8 Months)
Query!
Secondary outcome [6]
0
0
Time to First Worsening of the Brief Pain Inventory Short Form Modified (mBPI-sf) "Worst Pain Score"
Query!
Assessment method [6]
0
0
Time to first worsening of the brief pain inventory short form modified (mBPI-sf) "worst pain score" was defined as the time from the date of the first study drug dose (baseline date) to the first date of a "worst pain" score increase of greater than or equal to (=) 2 points from baseline. The mBPI-sf is an 11-item instrument used as a multiple-item measure of cancer pain intensity ranging from 0 (no pain or does not interfere) and ranged through 10 (pain as bad as you can imagine or completely interferes).
Query!
Timepoint [6]
0
0
Randomization through Follow-up (Up to 34.5 Months)
Query!
Secondary outcome [7]
0
0
Duration of Overall Response (DoR)
Query!
Assessment method [7]
0
0
The duration of overall response was defined for each participant with a best response of CR or PR and measured from the time measurement criteria are first met for CR or PR (whichever is first recorded) until the first date that disease is recurrent or objective disease progression or death due to any cause is observed (taking as reference for PD the smallest measurements recorded on study).
Query!
Timepoint [7]
0
0
Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Up to 33.4 Months)
Query!
Secondary outcome [8]
0
0
Duration of Disease Control (DDC)
Query!
Assessment method [8]
0
0
Duration of disease control was defined for each participant with a best response of CR, PR, or stable disease (SD) as the time from randomization to the first date of disease progression or death due to any cause.
Query!
Timepoint [8]
0
0
Date of CR, PR, or SD to Objective Disease Progression or Death Due to Any Cause (Up to 35.8 Months)
Query!
Secondary outcome [9]
0
0
Pharmacokinetics (PK) Clearance of Olaratumab Mean Parameter Estimate
Query!
Assessment method [9]
0
0
The PK systemic clearance parameter estimates from the current analysis are listed together with the population PK model estimates.
Query!
Timepoint [9]
0
0
Cycle 1- 9: Day 1 and 8, Predose, 5 minutes Post dose and then every other cycle and follow-up (30 Days)
Query!
Secondary outcome [10]
0
0
PK: Volume of Distribution at Steady State (Vss) of Olaratumab: Mean Parameter Estimate
Query!
Assessment method [10]
0
0
The PK parameter estimates from the current analysis are listed together with the population PK model estimates. The Vss is the sum of central volume of distribution (V1) + peripheral volume of distribution (V2).
Query!
Timepoint [10]
0
0
Cycle 1- 9: Day 1 and 8; Predose, 5 Minutes Post dose and then every other cycle and follow-up (30 Days)
Query!
Eligibility
Key inclusion criteria
- Histologically confirmed diagnosis of advanced unresectable or metastatic soft tissue
sarcoma not amenable to curative treatment with surgery or radiotherapy. Participants
with Kaposi's sarcoma and gastrointestinal stromal tumors (GIST) will be excluded.
Note: Evidence of disease progression is required for participants that are not newly
diagnosed.
- Presence of measurable or nonmeasurable but evaluable disease as defined by the
Response Evaluation Criteria in Solid Tumors (RECIST 1.1, Eisenhauer et al. 2009).
- Performance status 0-1 on the Eastern Cooperative Oncology Group (ECOG) scale.
- The participant has not received any previous treatment with anthracyclines.
- The participant may have had any number of prior systemic cytotoxic therapies for
advanced/metastatic disease and are considered appropriate candidates for
anthracycline therapy. All previous anticancer treatments must be completed = 3 weeks
(21 days) prior to first dose of study drug.
- Availability of tumor tissue is required for study eligibility. The participant must
have consented to provide archived formalin-fixed paraffin embedded (FFPE) tumor
tissue or be subject to a pre-treatment re-biopsy of primary or metastatic tumor
tissue for future central pathology review and translational research (if archived
tissue is unavailable).
- Adequate hematologic, organ, and coagulation within 2 weeks (14 days) prior to
randomization.
- Left ventricular ejection fraction (LVEF) =50% assessed within 28 days prior to
randomization.
- Females of child-bearing potential must have a negative serum pregnancy test within 7
days prior to randomization.
- Females of child-bearing potential and males must agree to use highly effective
contraceptive precautions during the trial and up to 3 months following the last dose
of study drug.
- The participant has, in the opinion of the investigator, a life expectancy of at least
3 months.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Diagnosis of GIST or Kaposi sarcoma.
- Active central nervous system (CNS) or leptomeningeal metastasis (brain metastasis) at
the time of randomization. Participants with a history of a CNS metastasis previously
treated with curative intent (for example, stereotactic radiation or surgery) that
have not progressed on follow-up imaging, have been asymptomatic for at least 60 days
and are not receiving systemic corticosteroids and or/anticonvulsants, are eligible.
Participants with signs or symptoms of neurological compromise should have appropriate
radiographic imaging performed before randomization to rule out brain metastasis.
- Prior treatment with doxorubicin, epirubicin, idarubicin, and/or other anthracyclines
or anthracenediones; the participant has received treatment with olaratumab or has
participated in a prior olaratumab trial.
- Prior radiotherapy of the mediastinal/pericardial area or whole pelvis radiation.
- The participant has symptomatic congestive heart failure (CHF), left ventricular
dysfunction (LVEF < 50%), severe myocardial insufficiency, cardiac arrhythmia, or
cardiomyopathy.
- The participant has unstable angina pectoris, angioplasty, cardiac stenting, or
myocardial infarction within 6 months of randomization.
- The participant has a QT interval calculated using Bazett's formula (QTcB) interval of
>450 milliseconds (msec) for males and >470 msec for females on screening
electrocardiogram (ECG).
- Females who are pregnant or breastfeeding.
- Known allergy to any of the treatment components including a history of allergic
reactions attributed to compounds of chemical or biological composition similar to
olaratumab.
- The participant has a known active fungal, bacterial, or viral infection including
human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis (screening is not
required).
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
14/09/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
31/07/2024
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
509
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
0
0
Chris O'Brien Lifehouse - Camperdown
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Massachusetts
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Michigan
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Missouri
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Nebraska
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New Mexico
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New York
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
North Carolina
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Ohio
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Oregon
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Pennsylvania
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Tennessee
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Utah
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Virginia
Query!
Country [18]
0
0
Argentina
Query!
State/province [18]
0
0
BS
Query!
Country [19]
0
0
Argentina
Query!
State/province [19]
0
0
Buenos Aires
Query!
Country [20]
0
0
Argentina
Query!
State/province [20]
0
0
Santa Fe
Query!
Country [21]
0
0
Austria
Query!
State/province [21]
0
0
Wien
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Brussel
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Oost-Vlaanderen
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Leuven
Query!
Country [25]
0
0
Brazil
Query!
State/province [25]
0
0
RJ
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
São Paulo
Query!
Country [27]
0
0
Canada
Query!
State/province [27]
0
0
Alberta
Query!
Country [28]
0
0
Canada
Query!
State/province [28]
0
0
British Columbia
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
Kowloon
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
Quebec
Query!
Country [31]
0
0
Denmark
Query!
State/province [31]
0
0
Herlev
Query!
Country [32]
0
0
Finland
Query!
State/province [32]
0
0
Pirkanmaa
Query!
Country [33]
0
0
Finland
Query!
State/province [33]
0
0
Turku
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Côte-d'Or
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Rhône-Alpes
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Bordeaux
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Marseille CEDEX 05
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Paris
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Toulouse cedex 9
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Villejuif Cedex
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Baden-Württemberg
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Bayern
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Nordrhein-Westfalen
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Berlin
Query!
Country [45]
0
0
Hungary
Query!
State/province [45]
0
0
Budapest
Query!
Country [46]
0
0
Israel
Query!
State/province [46]
0
0
Ramat Gan
Query!
Country [47]
0
0
Israel
Query!
State/province [47]
0
0
Jerusalem
Query!
Country [48]
0
0
Israel
Query!
State/province [48]
0
0
Tel Aviv Jaffa
Query!
Country [49]
0
0
Italy
Query!
State/province [49]
0
0
Lombardie
Query!
Country [50]
0
0
Italy
Query!
State/province [50]
0
0
Milano
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Sicilia
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Torino
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Aichi
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Chiba
Query!
Country [55]
0
0
Japan
Query!
State/province [55]
0
0
Hokkaido
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Osaka
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Saitama
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Tokyo
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Fukuoka
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Okayama
Query!
Country [61]
0
0
Korea, Republic of
Query!
State/province [61]
0
0
Gyeonggi-do
Query!
Country [62]
0
0
Korea, Republic of
Query!
State/province [62]
0
0
Korea
Query!
Country [63]
0
0
Korea, Republic of
Query!
State/province [63]
0
0
Seoul
Query!
Country [64]
0
0
Mexico
Query!
State/province [64]
0
0
Baja California
Query!
Country [65]
0
0
Mexico
Query!
State/province [65]
0
0
Jalisco
Query!
Country [66]
0
0
Mexico
Query!
State/province [66]
0
0
Nuevo Leon
Query!
Country [67]
0
0
Mexico
Query!
State/province [67]
0
0
Yucatán
Query!
Country [68]
0
0
Mexico
Query!
State/province [68]
0
0
San Luis Potosi
Query!
Country [69]
0
0
Netherlands
Query!
State/province [69]
0
0
Limburg
Query!
Country [70]
0
0
Netherlands
Query!
State/province [70]
0
0
Groningen
Query!
Country [71]
0
0
Netherlands
Query!
State/province [71]
0
0
Leiden
Query!
Country [72]
0
0
Netherlands
Query!
State/province [72]
0
0
Nijmegen
Query!
Country [73]
0
0
Netherlands
Query!
State/province [73]
0
0
Rotterdam
Query!
Country [74]
0
0
Poland
Query!
State/province [74]
0
0
Warszawa
Query!
Country [75]
0
0
Russian Federation
Query!
State/province [75]
0
0
Tatarstan Republic
Query!
Country [76]
0
0
Russian Federation
Query!
State/province [76]
0
0
Moscow
Query!
Country [77]
0
0
Russian Federation
Query!
State/province [77]
0
0
St. Petersburg
Query!
Country [78]
0
0
Spain
Query!
State/province [78]
0
0
Andalucía
Query!
Country [79]
0
0
Spain
Query!
State/province [79]
0
0
Barcelona
Query!
Country [80]
0
0
Spain
Query!
State/province [80]
0
0
Madrid
Query!
Country [81]
0
0
Spain
Query!
State/province [81]
0
0
Valencia
Query!
Country [82]
0
0
Sweden
Query!
State/province [82]
0
0
Lund
Query!
Country [83]
0
0
Switzerland
Query!
State/province [83]
0
0
Sankt Gallen
Query!
Country [84]
0
0
Switzerland
Query!
State/province [84]
0
0
Bern
Query!
Country [85]
0
0
Taiwan
Query!
State/province [85]
0
0
Taipei City
Query!
Country [86]
0
0
Taiwan
Query!
State/province [86]
0
0
Taipei
Query!
Country [87]
0
0
Taiwan
Query!
State/province [87]
0
0
Taoyuan Hsien
Query!
Country [88]
0
0
United Kingdom
Query!
State/province [88]
0
0
Greater London
Query!
Country [89]
0
0
United Kingdom
Query!
State/province [89]
0
0
Greater Manchester
Query!
Country [90]
0
0
United Kingdom
Query!
State/province [90]
0
0
Merseyside
Query!
Country [91]
0
0
United Kingdom
Query!
State/province [91]
0
0
South Yorkshire
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Eli Lilly and Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The main purpose of this study is to evaluate the efficacy of the combination of doxorubicin
plus the study drug known as olaratumab versus doxorubicin plus placebo in participants with
advanced or metastatic soft tissue sarcoma.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02451943
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Query!
Address
0
0
Eli Lilly and Company
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02451943
Download to PDF